The global pharmaceutical industry is undergoing a revolution driven by the recent advancements in biotechnology and new drug discovery techniques. One of the areas that is witnessing significant growth is the microbial fermentation process for producing Active Pharmaceutical Ingredients (APIs). Microbial fermentation involves using microorganisms like bacteria, fungi to produce therapeutic compounds through controlled biological processes. This technology is enabling drug manufacturers to develop complex molecules efficiently and sustainably.

Emergence of Microbial Fermentation as Primary Production Method

Traditionally, pharmaceutical APIs were synthesized through multiple chemical reaction steps that involved hazardous chemicals and by-products. However, microbial fermentation provides a "green" alternative to chemical synthesis by employing living cells to assemble complex molecules. It allows maximum atom efficiency and minimizes waste generation. Further, fermentation yields can be improved through metabolic engineering and process intensification technologies. All these advantages have led fermentation to become the primary production process for many blockbuster drugs. Presently over 150 APIs including antibiotics, hormones, and anticancer compounds are manufactured globally using microbial cells.

Asia Dominates Global Microbial API Production

The cost competitiveness and process expertise in Microbial Fermentation have enabled Asian countries especially China and India to emerge as global leaders in microbial API production. As per industry estimates, over 80% of the total worldwide fermentation capacity is located in Asia. China alone accounts for more than 50% of global supplies of common antibiotics and has the largest number of fermentation facilities. Other Asian nations like Singapore, South Korea and Taiwan are also positioning themselves as hubs for novel biologic drug substances manufacture. This has provided Asian pharmaceutical companies an edge over their Western counterparts in producing affordable generic drugs.

Expansion of Bacterial and Fungal Host Platforms

Early microbial fermentation focused majorly on bacterial workhorses like E. coli and S. cerevisiae. However, continuous R&D is unlocking the potential of new bacterial and fungal cell factories. Promising platforms currently under development include Corynebacterium, Pseudomonas, Streptomyces, Aspergillus and Yarrowia. Each microorganism offers unique advantages in terms of pathway contents, tolerance to industrial process conditions and product secretion abilities. Engineering novel hosts enables expression of recalcitrant enzymes and synthesis of structurally complex biomolecules. This expands the chemical space accessible through fermentation, allowing more drugs to be manufactured sustainably.

Emerging Areas in Microbial API Field

Several emerging areas are gaining attention in the global microbial API industry:

- Plasmid-free fermentation strains: Traditional strains used in industry harbor extrachromosomal elements which pose stability issues. Next-gen strains devoid of plasmids offer robustness and scalability.
- Fed-batch and continuous fermentation: Advanced process technologies allow maximizing cell density and prolonging production phases, significantly improving titers.
- Synthetic biology tools: Precision genome editing tools like CRISPR expedite strain optimization by enabling rapid, multiplex gene alterations.
- Production of biologics: Microbial cells are engineered to produce therapeutic proteins, monoclonal antibodies, fusion proteins, peptides for treatment of cancer, metabolic disorders.
- Sustainable chemistry: Fermentation coupled with downstream chemical catalysis enables end-to-end "green" synthesis of pharmaceutical building blocks.

Outlook

The global microbial API market size is projected to grow at over 7% CAGR during 2023-2028, reaching a valuation of $150 billion. Cost-effectiveness, brand exclusivity, and evolving regulatory guidelines are stimulating continuous R&D investments into novel fermentation processes. Asian manufacturers are working on expanding capacity to maintain stronghold. The emergence of synthetic biology and futuristic technologies like computer-aided strain design will further strengthen the role of microbial fermentation in developing new drug modalities and democratizing global healthcare.

Get more insights on Microbial API